Objective: To evaluate the intrinsic resting functional connectivity of the default mode network (DMN), salience network (SN), and central executive network (CEN) network in women with chronic migraine (CM), and whether clinical features are associated with such abnormalities.
The exact pathophysiologic underpinnings of chronic migraine (CM) are unknown. The current understanding suggests an interplay between genetics and environmental risk factors. 1 Given that pain perception has various affective influences, beyond the immediate processing of painful sensations, cortical modulation of the limbic areas may be central in how patients perceive pain. 2, 3 Therefore, a critical question to be answered is how the resting-state functional brain connectivity adapts to the continuous processing and modulation of pain in CM.
Intrinsic functional brain networks (IFBN) such as default mode network (DMN), salience network (SN), and central executive network (CEN) are state-dependent, spatial topographies consisting of functionally correlated brain regions, which may be pathophysiologic surrogates of the neural activities. 4, 5 Previous resting-state functional MRI (rs-fMRI) studies in episodic migraine (EM) have demonstrated atypical focal connectivity within the DMN, SN, and CEN. [6] [7] [8] [9] [10] [11] There is a paucity of data on overall rs-fMRI connectivity patterns and association with clinical characteristics in CM interictally. Such an approach to the brain connectivity may be important given that pain awareness is dependent upon a complex array of parallel processes that adapt to representation of internal and external stimuli in real time, instead of passive primary sensory interpretation. 12 We simultaneously evaluated the 3 IFBN and their relationships with clinical characteristics. We hypothesize that the connectivity in each IFBN will be decreased in CM, and clinical characteristics will be associated with such connectivity abnormalities; in addition, the IFBN may be differentially affected in CM with medication overuse headache (MOH) and without MOH.
METHODS Participants. Women were eligible for the study if they were 18 years or older, met diagnostic criteria fulfilling International Classification of Headache Disorders (ICHD)-III-beta for CM as determined by a headache specialist, or were nonpain, nonheadache controls. CM subgroups were characterized based on medication overuse status (with or without) per ICHD-III-beta diagnostic criteria. Participants were excluded if they had MRI contraindication, neurologic or pain disorders other than CM, any chronic illness (i.e., hypertension, diabetes, hepatic, renal, chronic inflammatory, or infectious disease), or inability to follow study protocol while completing assessments.
All CM participants were age-and sex-matched to healthy controls. Controls were excluded if they had a family history of migraine or used over the counter/prescription pain medication for more than 5 days per month. CM participants were scanned at their baseline level of pain, at least 24 hours outside of their acute pain exacerbation period; any participant who came in within 24 hours of acute pain exacerbation was rescheduled.
All participants underwent vital sign evaluation including body mass index (BMI) and a neurologic examination and completed a standardized questionnaire to ascertain demographics including age, sex, race, and educational level as well as clinical characteristics including (1) duration of migraine history, (2) duration of CM history, (3) family history of migraine, (4) current medications, (5) number of moderate to severe headache days per month, (6) location of migraine, (7) presence of aura, (8) headache-related disability as determined by the Headache Impact Test (HIT-6), (9) depression as determined by the Patient Health Questionnaire (PHQ-9), and (10) allodynia as measured by the Allodynia Symptom Checklist (ASC12). 13 Headache Impact Test. The HIT-6 is a validated questionnaire that consists of 6 items reflecting quality of life. Higher scores (range 36-78) indicate an increasing effect of headaches on daily functioning.
14 Patient Health Questionnaire. The PHQ-9 is a diagnostic measure for clinical depression. A score of $15 on the PHQ-9 is associated with a 68% sensitivity and 95% specificity for diagnosing major depressive disorder based on DSM-IV criteria. 15 Standard protocol approvals, registrations, and patient consents. The study protocol was approved by institutional review boards at the University of South Carolina. Written informed consent was obtained from all participants.
MRI. All participants were scanned on a Siemens (Munich, Germany) 3T scanner located at the McCausland Center for Brain Imaging (Columbia, SC). Some participants (5 CM and 5 controls) were scanned prior to a system hardware upgrade; however, any variance due to this upgrade was controlled for in our analysis by adding this as a nuisance regressor variable to general linear model using the Freedman-Lane approach. (To test any potential influence of including participants scanned prior to system hardware on our findings, we ran the same statistical analysis without these 10 participants and the overall results were still significant [,0.05]. Therefore, we chose to include all participants in the analysis and included the choice of head channel coil as a nuisance variable in the linear regression model. 16 ) Participants were instructed to keep their eyes closed, stay awake, relax, and think of nothing in particular during the resting-state scan. All conditions and lighting were consistent throughout the entire study for all participants.
The imaging parameters for the Trio (12-channel head coil) system consisted of a 6-minute high-resolution T1-weighted magnetization-prepared rapid gradient echo ( 2 , and using a transversal, descending, interleaved acquisition).
The imaging parameters for the Prisma (20-channel head coil) system included an acquisition of 6-minute highresolution T1-weighted MPRAGE scan (same parameters as Trio except for TE 4.11 ms) and a 15-minute resting-state functional imaging scan using a T2*-weighted BOLD contrast-sensitive sequence (TR 1,100 ms, TE 35 ms, 56 slices, 20% slice gap, flip angle 728, voxel size 2.4 3 2.4 3 2.0 mm 3 , FOV 216 mm 2 , and using a transversal, ascending, interleaved acquisition).
MRI processing. rs-fMRI preprocessing was completed using a combination of Statistical Parametric Mapping 12 (SPM12) software and custom MATLAB scripts. The pipeline consisted of standard procedures including motion correction, coregistration, normalization, frequency filtering (0.01-0.1 Hz bandpass), and spatial smoothing (8 mm full width at half maximum). For each network, a connectivity atlas was constructed using spherical (15 mm diameter) regions of interest (ROIs) centered on the peak Montreal Neurologic Institute (MNI) coordinates for the a priori network of DMN, SN, and CEN. 17, 18 The ROIs and their MNI coordinates used in each network are provided in table e-1 at Neurology.org and illustrated in figures 1-3 and figure e-1.
The DMN included ROIs (nodes) of the lateral parietal, medial prefrontal cortex, and precuneus. The SN includes regions of the dorsolateral prefrontal cortex (PFC), ventrolateral PFC (VLPFC), frontal pole, orbital frontal insula, dorsal anterior cingulate cortex, paracingulate cortex, sublenticular extended amygdala (subcallosal area), supramarginal gyrus, periaqueductal gray area, supplementary motor area/presupplementary motor area, substantia nigra/ventral tegmental area, superior temporal, temporal pole, ventral striatum/pallidum, dorsomedial thalamus, and hypothalamus. The CEN includes regions of the dorsolateral PFC (DLPFC) region of frontal eye fields, dorsal medial PFC, DLPFC, VLPFC, orbital frontoinsular, inferior frontal gyrus, inferior temporal, lateral parietal, anterior thalamus, dorsal caudate, and ventromedial caudate.
Statistical analysis. To create a functional connectivity matrix for each participant, we first extracted the BOLD time series from each ROI that was defined a priori within a network. Then, a functional connectivity matrix (for each separate network) was created using the Pearson correlation coefficient for each pair of ROIs in a network. All Pearson correlation (r) values were then Fisher Z transformed to produce the final functional connectivity matrices (for each participant and each network), which were used in the analysis. To investigate the overall functional coherence of a network, the Fisher Z transformed correlation coefficient values between all pairs of ROIs in each network were averaged separately for each participant to obtain the overall network functional connectivity. For each network, a 1-tailed, permuted t test was used to evaluate if there was significant decrease in the overall network connectivity in CM as compared to controls, and a 2-tailed permuted t test was used to determine if differences exist between CM with MOH and CM without MOH. Each statistical test employed a permutation method, using 10,000 permutations, to control for multiple comparisons. 19 To evaluate the relationship between the covariates (clinical features as listed in table 1), we first used a Pearson correlation analysis, x 2 , and one-way analysis of variance. Subsequently, after removing uncorrelated variables, a multivariate linear regression model was used to determine if any of the clinical features contributed to changes in functional connectivity strength for each network. Confounders, such as age, race, and BMI, were controlled for in this model. Correlations with p # 0.05 were considered significant (SAS 9.4). In addition, we used a 2-tailed t test to evaluate if there was significant effect on network connectivity in CM participants who used daily migraine preventive medications compared to those who did not.
RESULTS Participants. A total of 56 women were recruited between January 2015 and August 2016 from the University of South Carolina headache clinic. Among the CM participants (n 5 33), 4 were excluded for motion artifact (n 5 1), incidental finding on T1 (n 5 2), and the presence of nonmigrainerelated pain during the scan (n 5 1).
Among the controls (n 5 23), 4 were excluded for claustrophobia (n 5 2), motion artifact (n 5 1), and an incidental finding on T1 (n 5 1). Individual characteristics for each group are summarized in table 1 for all participants.
Of the CM participants, 16 had the secondary diagnosis of MOH for the abuse of opioids (n 5 8), triptans (n 5 9), combined analgesics (n 5 14), and combination of triptans with opioids or nonsteroidal anti-inflammatory drugs (n 5 10). Among 29 CM participants, 15 used daily migraine preventive prophylaxis medications (Topamax or propranolol).
Network differences. In all networks investigated (DMN, SN, and ECN), we found that there was significant decreased overall network connectivity for all CM participants, regardless of MOH status, when compared to controls. Averages and significance values for each CM group and their set of matched controls are listed in table 2. There was no difference between the overall network connectivity strength between CM with MOH when compared to CM without MOH. There were also no differences in overall network connectivity strength of DMN (p 5 0.490), SN (p 5 0.386), or CEN (p 5 0.922) between CM participants who used daily migraine prophylaxis as compared to those who did not.
Clinical characteristics. A multivariate linear regression model was used to analyze the relationship between the overall network connectivity for targeted networks (DMN, SN, and CEN) and clinical characteristics. After adjusting for covariates, we found that number of moderate to severe headache days and allodynia severity were correlated with the SN connectivity strength. For each increase of moderate to severe headache day, the connectivity strength of the SN was predicted to decrease by 0.0094 (p 5 0.0028). For each increase in allodynia severity (measured by ASC), the connectivity strength of the SN was predicted to increase by 0.0112 (p 5 0.0111).
We also found that the number of moderate to severe headache days per month was negatively correlated with the CEN connectivity strength. For each increase of moderate to severe headache day, the connectivity strength of the CEN was predicted to decrease by 0.0058 (p 5 0.0147).
In addition, HIT-6 (p 5 0.3442) and PHQ-9 (p 5 0.8092) were not correlated with network connectivity changes in the SN and CEN. We did not find any association between any clinical attributes evaluated and connectivity changes in the DMN. DISCUSSION In this study, focusing on the 3 main  IFBN (DMN, SN, and CEN) in the interictal state of CM patients, we found that all 3 IFBN were less coherent, regardless of MOH status. Moreover, we report that 2 of the clinical attributes are closely associated with the changes of the SN and CEN in CM: first, higher headache frequency (moderate to severe) was associated with decreased connectivity strengths in both SN and CEN; second, allodynia severity was associated with increased connectivity in the SN.
Given that a lower correlation within an IFBN implies that the functional components (or nodes) within the network are not oscillating in synchrony, or not following a similar time course, our findings suggest that CM patients have an overall diminished coherence, or functional coactivation, interictally within these important IFBN. Essentially, a change in the time course for at least one or more of the nodes in a network may disrupt the synchrony of the entire network.
In normal human cognition, attention to internal or external stimuli plays a major part in how they become behaviorally relevant. Normally this is how any stimulus is deemed painful, pleasant, neutral, and worthy of a response. This process has 2 ways of dealing with stimuli: a bottom-up filtering process and top-down sensitivity control. 20 Filtering and amplification of specific stimuli is thought to occur at multiple hierarchical levels, and at each level, filters may choose those that are of biological importance. As this happens, DMN activity generally fluctuates with SN and CEN activation. In particular, the SN is now thought to be a higher level selection and filtration network for stimuli akin to this. 21 It has been suggested that this may be how pain captures attention and becomes salient. 22 Chronic pain is a complex, multidimensional sensory experience that is a composite of 3 domains: sensory, affective, and cognitive. 23, 24 As CM is a form of chronic pain, susceptibility to this chronic headache disorder would likely occur due to dysfunctional mechanisms that regulate the ways in which these domains react to exogenous and endogenous stimuli. 25 Epidemiologic studies have demonstrated that several demographic (age, female sex, lower educational status) and headache-related characteristics, including MOH and cutaneous allodynia, are associated with an increased risk of CM. [26] [27] [28] In our study, allodynia and headache frequency are associated with the connectivity abnormalities. This is suggestive of differential modulations that are simultaneously occurring within the SN and CEN. Specifically, while nodes within SN and CEN are functioning less synchronously with increased headache frequency, certain functional 29 and disrupted addiction/reward dopaminergic pathway, 30 which could trigger more widespread disruption to networks, as compared to CM without MOH. Given that there are many unique pairs of intranetwork connections in the DMN, SN, and CEN (6, 136, and 351 respectively), investigation of the intranetwork nodal-tonodal connectivity would shed light on subtle underpinnings between CM with MOH and CM without MOH, interictally. This work is currently in progress.
Our study has several limitations. First, we cannot be certain that our findings are a consequence of CM or causal. Second, as we did not have a cohort of EM in this study, we cannot generalize to other migraine populations. Third, 15 CM participants were on daily migraine prophylaxis medications; however, further analysis on connectivity changes did not reveal any differences as compared to those who did not take any preventive medication. Fourth, coherence or functional coactivation does not equal electrophysiologic coactivation; this is a limitation of rs-fMRI methodology. However, rs-fMRI is a valid surrogate for neural activity when no active task is involved. 5 Finally, participants were not matched according to anxiety/depression scale; therefore we cannot exclude the possibility that some of the changes in connectivity may be related to anxiety/ depression. However, using the linear regression model, we did not find PHQ-9 associated with any of the targeted networks' connectivity changes.
We suggest that these intrinsic networks' connectivity may be used as potential biomarkers for the underlying impaired neural networks associated with CM, and as such may have potential as surrogates for evaluating the efficacy of both pharmacologic and nonpharmacologic interventions in CM. We envisage further studies to validate our findings and to refine some of these limitations.
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